Please assess the completion status of the following clinical trial:

Trial Title: Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. de novo or transformed Diffuse large B cell non-Hodgkin lymphoma (DLBCL). DLBCL-like lymphomas allowed:~   * Epstei-Barr virus (EBV)+ DLBCL in elderly,~  * DLBCL with chronic inflammation,~  * Primary cutaneous DLBCL, leg type,~  * B cell lymphoma unclassifiable - between DLBCL and Burkitt lymphoma,~  * B cell lymphoma unclassifiable - between large B cell lymphoma and classical Hodgkin lymphoma,~  * Anaplastic lymphoma kinase (ALK)+ large B cell lymphoma,~  * T cell histiocyte rich large B cell lymphoma~  * Primary mediastinal B cell lymphoma~  * Follicular grade 3 B cell lymphoma~2. Refractory or relapsed disease to \>/= 1 prior treatment regimen: should include autologous stem cell transplant unless patient refused or ineligible.~3. Age \> 18 years old~4. Eastern Cooperative Oncology Group (ECOG) performance status \<2.~5. Measurable or evaluable disease by physical exam, radiographs or bone marrow involvement~6. Frozen tumor or paraffin-embedded sample available.~7. 3-4 core fresh/fresh-frozen biopsy specimens available. Leukapheresis may be done for patients with leukocytosis.~8. Laboratory Values per protocol.~Exclusion Criteria:~1. Laboratory Values~   * Grade 3 hyperlipidemia (Serum cholesterol \>400mg/dl or serum triglycerides \>5 x ULN)~  * Serum Glucose \> 250mg/dl on \>/= 2 checks on 2 separate days~  * Diabetics accepted if sugars controlled~2. Unlimited prior chemotherapy regimens, however:~   * No prior exposure to RAD001 or LBH589 or drugs that target mTOR (sirolimus, temsirolimus, etc) or HDAC (vorinostat)~     * No valproic acid during study or 5 days preceding start of first drug~  * No chemotherapy, biologics or immunotherapy \< 2 weeks before registration (6 weeks if last received bis-chloroethylnitrosourea (BCNU) or mitomycin C). Subjects must be recovered from therapy-related non-hematological toxicities to \< grade 1 or baseline if started with \> grade 1 toxicity.~  * No time limit for radiation prior to registration.~  * No radioimmunotherapy \< 2 months prior to registration. Subjects must be recovered from therapy-related toxicities to \< grade 1 or baseline if started with \> grade 1 toxicity.~  * No prior allogeneic stem cell transplantation unless allogeneic engraftment is \<2%.~  * Subjects receiving chronic, systemic treatment with corticosteroids = to \>20mg of prednisone per day.~     * Subjects receiving replacement for adrenal insufficiency allowed.~    * Topical or inhaled corticosteroids allowed.~3. History of other primary malignancy \< 3 years ago, except inactive basal, squamous cell carcinoma of the skin or superficial melanoma only requiring excision, prostate cancer with a prostate specific antigen (PSA) stable for \>/=3 months, carcinoma in situ of cervix.~4. Major surgery \< 4 weeks before or Minor surgery \< 2 weeks before registration. Subjects must be recovered from toxicities to \< grade 1 or baseline if started with \> grade 1 toxicity.~5. Investigational drugs \< 4 weeks prior to registration.~6. Impaired Cardiac Function per protocol.~7. Pregnant or breastfeeding females or adults of reproductive potential not using effective birth control~8. Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) \< 40% if tested (per protocol).~9. Impaired lung function: O2 saturation 88% or less at rest on room air by Pulse Oximetry.~10. Immunization with live attenuated vaccines \< 1 week of study entry~11. Impaired GI function or GI disease that may alter absorption of RAD001 or LBH589~12. Concurrent severe \&/or uncontrolled medical conditions~13. Medications with risk of prolonging QT interval or inducing torsade de pointes or interacting with LBH589 and RAD001 may be used per the protocol.~14. Active bleeding tendency~15. Positive for HIV.~16. Positive for Hepatitis C virus (HCV).~17. History of non-compliance to medical regimens.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1a (RAD001 followed by LBH589) (Type: EXPERIMENTAL): Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest.
- Arm 1b (LBH589 followed by RAD001) (Type: EXPERIMENTAL): Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest.
- Doublet (Combination RAD001 and LBH589) (Type: EXPERIMENTAL): Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues